The PHASE3 study (NCT06347003) evaluating plozasiran for severe hypertriglyceridemia completed its primary study on 2026-06-12. This trial enrolled 446 adult participants to assess the safety and efficacy of the investigational drug.
Background
Plozasiran (ARO-APOC3) is an investigational drug being studied for the treatment of severe hypertriglyceridemia (SHTG). This condition is characterized by abnormally high levels of triglycerides in the blood.
Trial design
The study, identified as NCT06347003, is a PHASE3 trial that enrolled 446 adult participants with severe hypertriglyceridemia. Participants were randomized to receive either plozasiran injection or placebo over 4 doses administered once every 3 months. The trial's primary objective is to evaluate the safety and efficacy of plozasiran.
What this means
The primary completion of this PHASE3 study signifies that data collection for the main endpoints has concluded. The next stage involves the analysis of the collected data to determine the safety and efficacy profile of plozasiran in adults with severe hypertriglyceridemia. The results from this trial will be crucial in evaluating plozasiran's potential role as a new therapeutic option for this condition.
Source
This information was sourced from ClinicalTrials.gov, documenting the primary completion of trial NCT06347003 on 2026-06-12. The study details are available on clinicaltrials.gov.